Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John P Moore

Showing results (271-280 of 321) with videos related to

Pageof 33
Sort By:
Cell Reports. Medicine|May 18, 2022
Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibodyBehnaz Heydarchi, Danielle S Fong, Hongmei Gao, et al.
Pathogens & Immunity|June 17, 2021
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in SalivaThomas J Ketas, Devidas Chaturbhuj, Victor M Cruz Portillo, et al.
American Journal of Obstetrics & Gynecology MFM|November 5, 2022
Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant personsMalavika Prabhu, Yawei J Yang, Carrie D Johnston, et al.
Plos Pathogens|September 27, 2013
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesRogier W Sanders, Ronald Derking, Albert Cupo, et al.
Plos Pathogens|August 25, 2021
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primatesJelle van Schooten, Marlies M van Haaren, Hui Li, et al.
NPJ Vaccines|February 10, 2021
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticlesPhilip J M Brouwer, Aleksandar Antanasijevic, Marlon de Gast, et al.
Plos Pathogens|August 12, 2020
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogensAleksandar Antanasijevic, George Ueda, Philip J M Brouwer, et al.
Journal of Virology|August 27, 2025
A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimersDevidas N Chaturbhuj, Kwinten Sliepen, Albert Cupo, et al.
Science (New York, N.Y.)|January 17, 2004
Public health. A sound rationale needed for phase III HIV-1 vaccine trialsDennis R Burton, Ronald C Desrosiers, Robert W Doms, et al.
Plos Pathogens|May 10, 2013
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycansJean-Philippe Julien, Devin Sok, Reza Khayat, et al.
Pageof 33

Showing results (271-280 of 321) with videos related to

Sort By:
Pageof 33
Cell Reports. Medicine|May 18, 2022
Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibodyBehnaz Heydarchi, Danielle S Fong, Hongmei Gao, et al.
Pathogens & Immunity|June 17, 2021
Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in SalivaThomas J Ketas, Devidas Chaturbhuj, Victor M Cruz Portillo, et al.
American Journal of Obstetrics & Gynecology MFM|November 5, 2022
Longitudinal antibody response kinetics following SARS-CoV-2 messenger RNA vaccination in pregnant and nonpregnant personsMalavika Prabhu, Yawei J Yang, Carrie D Johnston, et al.
Plos Pathogens|September 27, 2013
A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodiesRogier W Sanders, Ronald Derking, Albert Cupo, et al.
Plos Pathogens|August 25, 2021
Antibody responses induced by SHIV infection are more focused than those induced by soluble native HIV-1 envelope trimers in non-human primatesJelle van Schooten, Marlies M van Haaren, Hui Li, et al.
NPJ Vaccines|February 10, 2021
Immunofocusing and enhancing autologous Tier-2 HIV-1 neutralization by displaying Env trimers on two-component protein nanoparticlesPhilip J M Brouwer, Aleksandar Antanasijevic, Marlon de Gast, et al.
Plos Pathogens|August 12, 2020
Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogensAleksandar Antanasijevic, George Ueda, Philip J M Brouwer, et al.
Journal of Virology|August 27, 2025
A modification to heptad repeat 1 of gp41 improves yield and/or quality of soluble pre-fusion HIV-1 envelope glycoprotein trimersDevidas N Chaturbhuj, Kwinten Sliepen, Albert Cupo, et al.
Science (New York, N.Y.)|January 17, 2004
Public health. A sound rationale needed for phase III HIV-1 vaccine trialsDennis R Burton, Ronald C Desrosiers, Robert W Doms, et al.
Plos Pathogens|May 10, 2013
Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycansJean-Philippe Julien, Devin Sok, Reza Khayat, et al.
Pageof 33